RESUMO
INTRODUCCIÓN: Las porfirias hepáticas agudas (PHA): porfiria intermitente aguda (PIA), porfiria variegata (PV) y coproporfiria hereditaria (CH), son trastornos metabólicos monogénicos y autosómicos dominantes asociados con la deficiencia de enzimas que participan en la biosíntesis del grupo hemo en el hígado. La deficiencia del grupo hemo en el organismo originado por la mutación de alguna de estas enzimas provoca aumento en los niveles de porfobilinógeno (PBG) y ácido aminolevulínico (ALA) en orina, heces y plasma1 . Los síntomas típicos de un ataque agudo de porfiria son: neuroviscerales (dolor abdominal, náuseas, vómitos, constipación), neuropatía periférica ascendente (paresia, parálisis), disfunción autonómica (hipertensión, taquicardia), desequilibrio hidroelectrolítico (hiponatremia), psiquiátricos (ansiedad, agitación, depresión, psicosis aguda, manía, alucinaciones) y neurológicos (convulsiones, encefalopatía, coma)2,3. El tratamiento de estos pacientes es limitado. La terapia primaria se basa en la ingesta calórica (infusión con dextrosa), tratamiento sintomático y terapia de fluidos4. La hemina humana, al reducir el déficit del grupo hemo, inhibe por retroalimentación la actividad de delta-amino-levulínico sintetasa (enzima clave en la síntesis de las porfirinas), lo que reduce la producción de porfirinas y de precursores tóxicos (ALA y PBG) del grupo hemo5 . La hemina humana tiene aprobación por la Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS)6 con la indicación para el tratamiento de ataques agudos de porfiria hepática (porfiria aguda intermitente, porfiria variegata, coproporfiria hereditaria). No tiene aprobación para esta indicación por la Food and Drug Administration (FDA)7 ni por la European Medicines Agency (EMA). EVALUACIONES DE TECNOLOGÍAS: La Haute Autorité de Santé (HAS) (2014) 13, señala que hemina humana tiene una opinión favorable para su reembolso en el uso hospitalario, como tratamiento de primera línea de los ataques agudos de porfiria hepática (porfiria intermitente aguda, porfiria variegata y coproporfiria hereditaria). IMPLICACIONES ECONÓMICAS: La introducción de hemina humana representaría un incremento en el gasto aproximado al 0.0045% sobre el presupuesto asignado a medicamentos en el Sistema Nacional de Salud14. Si bien el impacto presupuestal estimado del uso de hemina humana no parece significativo, cabe señalar lo siguiente: 1) Se observa que el medicamento está enfocado al tratamiento de ataques agudos de porfiria hepática, es decir, es un medicamento cuyo objetivo principal no es curar la enfermedad, sino el manejo de los signos y síntomas de un evento particular (ataque agudo) derivado de una complicación (crisis) de la porfiria hepática. En este sentido, el uso de hemina humana en el tratamiento de pacientes con porfiria hepática representa un incremento en el costo total de tratamiento, pues es una terapia adyuvante y no sustitutiva de la terapia sintomática actualmente utilizada, según la evidencia clínica disponible. 2) Se debe considerar que, al cabo de 5 años, solamente el 25% de pacientes recibiría dicho tratamiento 3) Es necesario evaluar el tratamiento de los ataques agudos de otras modalidades de porfiria (PV y CH).
Assuntos
Humanos , Porfirias Hepáticas/tratamento farmacológico , Porfiria Aguda Intermitente/tratamento farmacológico , Coproporfiria Hereditária/tratamento farmacológico , Porfiria Variegada/tratamento farmacológico , Hemina/uso terapêutico , Avaliação em Saúde , Eficácia , Análise Custo-BenefícioRESUMO
As porfirias são doenças raras que decorrem de deficiência enzimática em uma das oito enzimas que compõem a cadeia de biossíntese do heme e possuem manifestações clínicas variadas. Na maior parte das vezes, são distúrbios hereditários embora existam formas adquiridas. Apresentam ampla interação entre fatores genéticos e fatores ambientais. As manifestações clínicas dependem do tipo de porfirina acumulada, do local onde esta é produzida (fígado ou medula óssea), se acumula da maneira que a mesma é excretada e do mecanismo de toxicidade desta (neurotoxicidade, fotossensibilidade ou ambos). Relatamos um caso de uma paciente do sexo feminino com diagnóstico de cirrose hepática secundária à porfiria que possuía sobrecarga de ferro em exames laboratoriais, sendo descartada a presença de cirrose secundária à hemocromatose.
The porphyrias are rare diseases that result from enzyme deficiency in one of eighteen zymesthat make up the chainof heme biosynthesis and have varied clinical manifestations. In most cases are hereditary disorders, although there are acquired forms. They feature wide interaction between genetican denvironmental factors. Clinical manifestations depend on the accumulated porphyrin, the site where it is produced (liver orbone marrow) and accumulates in the way that it isexcretedand the mechanism of this toxicity (neurotoxicity, photo sensitivity or both). We report a case of a female patient diagnosed with liver cirrhosis secondary to porphyria who had iron overload in laboratory tests being discarded the presence of cirrhosis secondary to hemochromatosis.
Assuntos
Humanos , Feminino , Idoso , Porfirias , Porfirias Hepáticas , Hemocromatose , Cirrose Hepática , Fibrose , Porfiria Cutânea Tardia , Porfiria Aguda Intermitente , Porfiria VariegadaRESUMO
BACKGROUND/AIMS: The porphyrias are genetically heterogeneous diseases, and each mutation is exclusive to one or two families. Among the mutations responsible for variegate porphyria in our country, c.1042_1043insT stands out, since it was described only in Argentina and is present in about 40% of genetically diagnosed families. Thus, we hypothesized the possible existence of a common ancestor for the mutation in our population. METHODS: We conducted a study based on microsatellite (short tandem repeats) haplotypes. RESULTS: We found a common haplotype in all of the patients carrying the common mutation. The age of the mutation was estimated to be about 375 years. CONCLUSION: There is a recent founder effect in our population for this particular genetic alteration in variegate porphyria.
Assuntos
Efeito Fundador , Porfiria Variegada/genética , Argentina , Haplótipos , Humanos , Repetições de Microssatélites/genética , Mutação/genética , LinhagemRESUMO
BACKGROUND: A partial deficiency in Protoporphyrinogen oxidase (PPOX) produces the mixed disorder Variegate Porphyria (VP), the second acute porphyria more frequent in Argentina. Identification of patients with an overt VP is absolutely important because treatment depends on an accurate diagnosis but more critical is the identification of asymptomatic relatives to avoid acute attacks which may progress to death. METHODS: We have studied at molecular level 18 new Argentinean patients biochemically diagnosed as VP. PPOX gene was amplified in one or in twelve PCR reactions. All coding exons, flanking intronic and promoter regions were manual or automatically sequenced. For RT-PCR studies RNA was retrotranscripted, amplified and sequenced. PPOX activity in those families carrying a new and uncharacterized mutation was performed. RESULTS: All affected individuals harboured mutations in heterozygous state. Nine novel mutations and 3 already reported mutations were identified. Six of the novel mutations were single nucleotide substitutions, 2 were small deletions and one a small insertion. Three single nucleotide substitutions and the insertion were at exon-intron boundaries. Two of the single nucleotide substitutions, c.471G>A and c.807G>A and the insertion (c.388+3insT) were close to the splice donor sites in exons 5, 7 and intron 4 respectively. The other single nucleotide substitution was a transversion in the last base of intron 7, g.3912G>C (c.808-1G>C) so altering the consensus acceptor splice site. However, only in the first case the abnormal band showing the skipping of exon 5 was detected. The other single nucleotide substitutions were transversions: c.101A>T, c.995G>C and c.670 T>G that result in p.E34V, p.G332A and W224G aminoacid substitutions in exons 3, 10 and 7 respectively. Activity measurements indicate that these mutations reduced about 50% PPOX activity and also that they co-segregate with this reduced activity value. Two frameshift mutations, c.133delT and c.925delA, were detected in exons 3 and 9 respectively. The first leads to an early termination signal 22 codons downstream (p.S45fsX67) and the second leads to a stop codon 5 codons downstream (p.I309fsX314). One reported mutation was a missense mutation (p.G232R) and 2 were frameshift mutations: c.1082insC and 1043insT. The last mutation was detected in six new apparently unrelated Argentinean families. CONCLUSION: Molecular analysis in available family members revealed 14 individuals who were silent carriers of VP. Molecular techniques represent the most accurate approach to identify unaffected carriers and to provide accurate genetic counselling for asymptomatic individuals. The initial screening includes the insertion search.
Assuntos
Flavoproteínas/genética , Proteínas Mitocondriais/genética , Porfiria Variegada/genética , Protoporfirinogênio Oxidase/genética , Adolescente , Adulto , Éxons , Feminino , Mutação da Fase de Leitura , Triagem de Portadores Genéticos , Heme/biossíntese , Humanos , Masculino , Pessoa de Meia-Idade , Mutação de Sentido Incorreto , Reação em Cadeia da Polimerase , Porfiria Variegada/metabolismo , Análise de Sequência de DNARESUMO
Variegate porphyria (VP) results from a hereditary deficiency of protoporphyrinogen oxidase (PPOX) that is transmitted in an autosomal dominan fashion. The diagnosis is based on the clinical symptoms and is confirmed biochemically. Sometimes, however, these diagnostic tools reveal limitations in establishing the definitive diagnosis of the prevailing type of acute porphyria. In these patients, molecular genetic analyses can be useful. We performed molecular genetic studies in 13 Chilean families by PCR amplification of the PPOX gene, conformation sensitive gel electrophoresis, and automated DNA sequencing. In five symptomatic patients from different families, respectively, the biochemical data confirmed the diagnosis of VP. In seven other families, however, the biochemical studies were not conclusive. Furthermore, the original biochemical analysis in one clinically severely affected patient from a further family even suggested the diagnosis of erythropoietic protoporphyria (EPP). Beside the respective index patients, we studied 78 asymptomatic family members and 50 healthy, unrelated individuals for control purposes. In five families, the previous diagnosis of VP could be confirmed genetically. Further, half of the asymptomatic relatives revealed a mutation in the PPOX gene, consisting of three missense mutations and two deletion mutations. Mutation R168H that had been already described previously in German VP families was found in a Chilean family of German origin. Further, two novel missense mutations, designated L74P and G232S, could be detected. In four Chilean families, we found the deletion 1330deICT that had also been previously described in three Swedish VP families. The second deletion, 1239delTACAC, has not been described anywhere else but Chile and could be identified in seven families. One patient who was initially diagnosed with EPP turned out to be a compound heterozygote for mutations on both alleles of the PPOX gene. In conclusion, our molecular genetic analyses unequivocally confirmed the diagnosis of VP in seven families who originally had revealed inconclusive biochemical data. Further, early genetic analysis allows for the identification of asymptomatic mutation carriers, thereby offering the possibility of adequate counselling and the prevention of potentially life-threatening acute porphyric attacks.
Assuntos
Porfiria Variegada/genética , Protoporfirinogênio Oxidase/genética , Chile , Flavoproteínas/genética , Predisposição Genética para Doença , Humanos , Proteínas Mitocondriais/genética , Mutação , Porfiria Variegada/diagnóstico , Porfiria Variegada/enzimologiaRESUMO
Las porfirias son consecuencia de fallas en el metabolismo del hemo. Se clasifican según el tipo de sintomatología clínica prevalente o el órgano donde se expresa preferencialmente la falla metabólica. En general la deficiencia enzimática está asociada a mutaciones en los genes que codifican para cada una de las enzimas. Están descritos 7 tipos de porfiria diferentes. Se transmiten por carácter autosómico dominante a excepción de la PCE, la PHE y la NPA que son recesivas. Sin embargo, están reportadas variantes homocigotas para el resto de las porfirias de pronóstico y evolución mucho más grave que la forma heterocigota. La descripción de estos casos poco frecuentes, sus tratamientos y evolución, facilitarían tanto el diagnóstico diferencial de la porfiria como el conocimiento de las posibilidades terapéuticas en cada caso. Asimismo para las porfirias heterocigotas con manifestación infantil, su identificación temprana y tratamiento aseguraría una mejor evolución minimizando los riesgos asociados. Se han diagnosticado 5 casos de porfirias agudas en niñas: 2 de PAI, 2 de PV y 1 de CPH. Entre las porfirias cutáneas se presentan 25 casos de PCT infantil, el primer caso de PHE en Argentina, 4 casos de PCE infantil y 1 en un adulto y 2 casos de PPE con compromiso hepatobiliar.
The Porphyrias are a group of diseases resulting from partial deficiencies in one of the heme biosynthetic enzymes. These disorders can be classified on the basis of their clinical manifestations or according the organ where the metabolic deficiency is mainly expressed. In general this enzyme deficiency is associated with mutations in the genes which codify each enzyme. There are 7 types of Porphyrias. They are autosomal dominant disorders with the exception of PCE, PHE and NPA which are recessive. However, some rare and severe cases with recessive inheritance have also been reported. The description of these infrequent cases and their treatments and evolution would make easier the differential diagnosis of Porphyrias as well as the therapeutic possibilities to be applied in each case. Moreover, it is very important the early identification and treatment of infantile heterozygous porphyrias to avoid the risks of associatedd complications. In the CIPYP we have diagnosed 5 cases of infantil Acute Porphyrias: 2 PAI, 2 PV and 1 CPH. In the group of Cutaneous Porphyrias we present 25 cases of infantil PCT, the first case of PHE in Argentina, 4 cases of infantil PCE and 1 adult PCE and 2 cases of PPE with hepatic failure.
Assuntos
Humanos , Masculino , Feminino , Lactente , Pré-Escolar , Criança , Adolescente , Adulto , Pessoa de Meia-Idade , Porfirias/classificação , Diagnóstico Diferencial , Argentina/epidemiologia , Porfirias/terapia , Porfirias Hepáticas/diagnóstico , Porfiria Eritropoética/diagnóstico , Porfiria Hepatoeritropoética/diagnóstico , Porfiria Cutânea Tardia/diagnóstico , Porfiria Aguda Intermitente/diagnóstico , Coproporfiria Hereditária/diagnóstico , Porfiria Variegada/diagnóstico , Protoporfiria Eritropoética/diagnósticoRESUMO
Variegate porphyria (VP) results from a hereditary deficiency of protoporphyrinogen oxidase (PPOX) that is transmitted in an autosomal dominan fashion. The diagnosis is based on the clinical symptoms and is confirmed biochemically. Sometimes, however, these diagnostic tools reveal limitations in establishing the definitive diagnosis of the prevailing type of acute porphyria. In these patients, molecular genetic analyses can be useful. We performed molecular genetic studies in 13 Chilean families by PCR amplification of the PPOX gene, conformation sensitive gel electrophoresis, and automated DNA sequencing. In five symptomatic patients from different families, respectively, the biochemical data confirmed the diagnosis of VP. In seven other families, however, the biochemical studies were not conclusive. Furthermore, the original biochemical analysis in one clinically severely affected patient from a further family even suggested the diagnosis of erythropoietic protoporphyria (EPP). Beside the respective index patients, we studied 78 asymptomatic family members and 50 healthy, unrelated individuals for control purposes. In five families, the previous diagnosis of VP could be confirmed genetically. Further, half of the asymptomatic relatives revealed a mutation in the PPOX gene, consisting of three missense mutations and two deletion mutations. Mutation R168H that had been already described previously in German VP families was found in a Chilean family of German origin. Further, two novel missense mutations, designated L74P and G232S, could be detected. In four Chilean families, we found the deletion 1330deICT that had also been previously described in three Swedish VP families. The second deletion, 1239delTACAC, has not been described anywhere else but Chile and could be identified in seven families. One patient who was initially diagnosed with EPP turned out to be a compound heterozygote for mutations on both alíeles of the PPOX gene. In conclusion, our molecular genetic analyses unequivocally confirmed the diagnosis of VP in seven families who originally had revealed inconclusive biochemical data. Further, early genetic analysis allows for the identification of asymptomatic mutation carriers, thereby offering the possibility of adequate counselling and the prevention of potentially life-threatening acute porphyric attacks.
La porfiria variegata (PV), enfermedad de origen genético con forma de herencia autosómica dominante, se debe a deficiencia en la actividad protoporfirinógeno oxidasa (PPOX). Su diagnóstico se basa en antecedentes clínicos y se confirma con análisis bioquímicos. Éstos, en algunos casos, pueden presentar limitaciones para establecer el diagnóstico definitivo de la variedad de porfiria aguda, situación en que el estudio genético molecular puede resultar útil. Se efectuó estudio genético en trece familias chilenas usando amplificación del gen PPOX por PCR, electroforesis conformacional y secuenciación automática de DNA. Cinco de estas familias incluían pacientes índices sintomáticos con diagnóstico bioquímico establecido de PV; otras siete familias incluían pacientes índices con estudio bioquímico no concluyente de la variedad de porfiria aguda y, finalmente, una familia con diagnóstico previo de protoporfiria eritropoyética (PPE). Además, se estudiaron 78 familiares asintomáticos y 50 personas sanas, no relacionadas, como controles. En cinco familias el estudio genético confirmó el diagnóstico bioquímico previo de PV. El 50% de los familiares asintomáticos resultaron ser portadores de una mutación en el gen PPOX. Se identificaron tres mutaciones por sustitución de bases: la R168H, descrita en familias de origen alemán y dos nuevas mutaciones, designadas L74P y G232S. También se identificaron dos mutaciones por deleción de bases designadas 1330delCT y la 1239delTACAC. La primera, que había sido descrita previamente en tres familias suecas, se encontró en cuatro familias chilenas. La segunda se encontró en siete familias y no ha sido descrita previamente. El estudio genético permitió mostrar que un paciente que originalmente fue diagnosticado con PPE correspondía a un heterocigoto compuesto para dos mutaciones en el gen PPOX. En conclusión, los estudios moleculares permitieron confirmar el diagnóstico de PV en cinco familias, efectuar diagnóstico de PV en familias en las cuales los datos bioquímicos no eran concluyentes, corregir el diagnóstico original en una familia e identificar portadores asintomáticos entre los familiares de los pacientes índices. Los estudios genéticos moleculares ayudan a realizar un adecuado consejo genético a pacientes y familiares y hace posible practicar prevención de las crisis agudas de porfiria, las que son potencialmente mortales.
Assuntos
Humanos , Porfiria Variegada/genética , Protoporfirinogênio Oxidase/genética , Chile , Flavoproteínas/genética , Predisposição Genética para Doença , Mutação , Proteínas Mitocondriais/genética , Porfiria Variegada/diagnóstico , Porfiria Variegada/enzimologiaRESUMO
A 7-year-old Chilean boy presented with severe photosensitivity, blistering, erosions and scarring on sun-exposed areas of the body since the age of 6 months. Additionally, he showed a short stature and shortening of the fingers. Laboratory examination revealed greatly elevated protoporphyrin levels in the blood. Such biochemical findings can be observed in homozygous variants of usually autosomal dominantly inherited acute porphyrias such as variegate porphyria (VP) and hereditary coproporphyria, which usually do not become manifest before the second or third decade of life in heterozygotes. Using polymerase chain reaction-based techniques we identified a missense mutation in exon 7 on the paternal allele and a frameshift mutation in exon 13 on the maternal allele of the protoporphyrinogen oxidase gene that harbours the mutations underlying VP. This is the first homozygous case of VP in South America. As VP represents the most frequent type of acute porphyria not only in Chile but also in South Africa, more such cases could be expected in the future, particularly because a founder mutation for this disease has already been described in the Chilean and South African population.